Drug Trial Radar · NCT05964413
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
Last checked: Nov 19, 2026Latest source record: Nov 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
54
Actual
Start
Nov 1, 2023
Primary completion
Jul 11, 2025
Study completion Jul 11, 2025
Sponsor
- Lead sponsor
- InflaRx GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jul 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum
Conditions
- Pyoderma Gangrenosum
Interventions
vilobelimabDrug
vilobelimab infusion
PlaceboDrug
Placebo Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of treatment with vilobelimab compared to placeboTime frame: Week 1 to Week 26
Locations
50 sites in 10 countries. Site status is shown where the registry gives one.
Aby´s New Generation Research, Inc
Hialeah, Florida
Dermatology/University of Miami Hospital
Miami, Florida
University of Central Florida College of Medicine
Orlando, Florida
ForCare Clinical Research
Tampa, Florida
Advanced Medical Research, PC
Sandy Springs, Georgia
Brigham and Women´s Hospital
Boston, Massachusetts
University of North Carolina at Chapel Hill Department of Dermatology
Chapel Hill, North Carolina
Ohio State University Wexner Medical Cente OSU Dermatology West
Columbus, Ohio
Apex Clinical Research Center
Mayfield Heights, Ohio
Oregon Health and Science University
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
The University of Texas Health Science Center at Houston
Bellaire, Texas
Veracity Clinical Research Pty Ltd as trustee for the MLS Trust
Brisbane, Australia
Liverpool Hospital
Sydney, Australia
Premier Specialists
Kogarah, NewSouth Wales, Australia
The Alfred Hospital, Melbourne
Melbourne, Victoria, Australia
Hôpitaux Universitaires de Bruxelles
Anderlecht, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Hospital Edouard Herriot
Lyon, France
CHU de Nantes - Clinique dermatologique
Nantes, France
Saint Louis Hospital
Paris, France
CHU Toulouse Hospital Larrey
Toulouse, Occitanie, France
Charité - Universitätsmedizin Berlin, Department of Dermatology, Venereology and Allergology, Berlin, Germany
Berlin, Germany
University clinic Duesseldorf Department of Dermatology Heinrich-Heine-University Duesseldorf
Düsseldorf, Germany
Universitätsklinik für Dermatologie und Venerologie der MLU Halle
Halle, Germany
Universitätsklinikum Hamburg-Eppendorf, Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP)
Hamburg, Germany
University Hospital Leipzig AöR
Leipzig, Germany
Universitätshautklinik Tübingen
Tübingen, Baden Würrtemberg, Germany
Berge Hautklinik
Erlangen, Bavaria, Germany
Universitätsklinikum Heidelberg
Heidelberg, Bavaria, Germany
Klinik und Poliklinik für Dermatologie und Allergologie
München, Bavaria, Germany
University Hospital Würzburg, Department of Dermatology
Würzburg, Bavaria, Germany
Universitätsklinikum Frankfurt, Klinik für Dermatologie
Frankfurt am Main, Hesse, Germany
Catholic Clinic Bochum, Department of Dermatology
Bochum, Nordrhein-Westfalia, Germany
University of Essen, Germany
Essen, North Rhine-Westphalia, Germany
Department of Dermatology, Venerology and Oncodermatology, University of Pécs
Pécs, Hungary
Department of Dermatology and Allergology, University of Szeged
Szeged, Csongrad-Csanad, Hungary
Department of Dermatology, University of Debrecen
Debrecen, Hadju-Bihar, Hungary
IRCCS Policlinico di Sant'Orsola Alma Mater Studiorum - University of Bologna
Bologna, Italy
Fondazione IRCCS Ca´ Granda Ospedale Maggiore Policlinico SC Dermatologia
Milan, Italy
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.